Understanding efficacy end-points in studies of field-directed therapy for actinic keratosis

International Journal of Dermatology

Volumn 52, Issue 9, 2013, Pages 1063-1070

  Wolf, John E ^a,b   Rigel, Darrell S ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DICLOFENAC; EFLORNITHINE; FLUOROURACIL; IMIQUIMOD; TOPICAL AGENT; TRIAMCINOLONE;

ACTINIC KERATOSIS; ARTICLE; CLEARANCE; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; FOLLOW UP; HUMAN; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; TOPICAL TREATMENT; TREATMENT DURATION;

ADMINISTRATION, TOPICAL; CLINICAL TRIALS AS TOPIC; DERMATOLOGIC AGENTS; HUMANS; KERATOSIS, ACTINIC;

EID: 84882608600     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2012.05776.x     Document Type: Article

References (58)

1. Hubbs L, Tuleya S. Treating AKs: what are your best options? Skin Aging 2005; 13: 36-42.
2. Criscione VD, Weinstock MA, Naylor MF, et al. Actinic keratoses: natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer 2009; 115: 2523-2530.
3. Stockfleth E. Topical management of actinic keratosis and field cancerization. G Ital Dermatol Venereol 2009; 144: 459-462.
4. Lee AD, Jorizzo JL. Optimizing management of actinic keratosis and photodamaged skin: utilizing a stepwise approach. Cutis 2009; 84: 169-175.
5. Berman B, Bienstock L, Kuritzky L, et al. Actinic keratoses: sequelae and treatments. Recommendations from a consensus panel. J Fam Pract 2006; 55(Suppl): 1-8.
6. Anderson L, Schmieder GJ, Werschler WP, et al. Randomized double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis. J Am Acad Dermatol 2009; 60: 934-943.
7. Huyke C, Reuter J, Rödig M, et al. Treatment of actinic keratoses with a novel betulin-based oleogel. A prospective, randomized, comparative pilot study. J Dtsch Dermatol Ges 2009; 7: 128-133.
8. ClinicalTrials.gov. (2010) Green tea extract in treating patients with actinic keratosis [WWW document]. Available at: http://clinicaltrials.gov/show/NCT00005097 [accessed on 13 October 2011].
9. Szeimies RM, Bichel J, Ortonne JP, et al. A phase II dose-ranging study of topical resiquimod to treat actinic keratosis. Br J Dermatol 2008; 159: 205-210.
10. Stockfleth E, Meyer T, Benninghoff B, et al. A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses. Arch Dermatol 2002; 138: 1498-1502.
11. Jorizzo J, Dinehart S, Matheson R, et al. Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head. J Am Acad Dermatol 2007; 57: 265-268.
12. Lebwohl M, Dinehart S, Whiting D, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol 2004; 50: 714-721.
13. Korman N, Moy R, Ling M, et al. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials. Arch Dermatol 2005; 141: 467-473.
14. Szeimies RM, Gerritsen MJ, Gupta G, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled clinical trial with histology. J Am Acad Dermatol 2004; 51: 547-555.
15. Salasche SJ, Levine N, Morrison L. Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: an open-label trial. J Am Acad Dermatol 2002; 47: 571-577.
16. Alomar A, Bichel J, McRae S. Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head. Br J Dermatol 2007; 157: 133-141.
17. Krawtchenko N, Roewert-Huber J, Ulrich M, et al. A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol 2007; 157(Suppl 2): 34-40.
18. Stockfleth E, Sterry W, Carey-Yard M, Bichel J. Multicentre, open-label study using imiquimod 5% cream in one or two 4-week courses of treatment for multiple actinic keratoses on the head. Br J Dermatol 2007; 157(Suppl 2): 41-46.
19. Ulrich C, Bichel J, Euvrard S, et al. Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients. Br J Dermatol 2007; 157(Suppl 2): 25-31.
20. Tanghetti E, Werschler P. Comparison of 5% 5-fluorouracil cream and 5% imiquimod cream in the management of actinic keratoses on the face and scalp. J Drugs Dermatol 2007; 6: 144-147.
21. Rivers JK, Rosoph L, Provost N, Bissonnette R. Open-label study to assess the safety and efficacy of imiquimod 5% cream applied once daily three times per week in cycles for treatment of actinic keratoses on the head. J Cutan Med Surg 2008; 12: 97-101.
22. Stockfleth E, Ulrich C, Lange-Asschenfeldt B, et al. Treatment of multiple, multiform actinic keratoses on the head with imiquimod 5% cream. Eur J Dermatol 2009; 19: 355-359.
23. Sotiriou E, Apalla Z, Maliamani F, et al. Intraindividual, right-left comparison of topical 5-aminolevulinic acid photodynamic therapy vs. 5% imiquimod cream for actinic keratoses on the upper extremities. J Eur Acad Dermatol Venereol 2009; 23: 1061-1065.
24. Gebauer K, Shumack S, Cowen PS. Effect of dosing frequency on the safety and efficacy of imiquimod 5% cream for treatment of actinic keratosis on the forearms and hands: a phase II, randomized, placebo-controlled trial. Br J Dermatol 2009; 161: 897-903.
25. Jorizzo J, Weiss J, Furst K, et al. Effect of a 1-week treatment with 0.5% topical fluorouracil on occurrence of actinic keratosis after cryosurgery: a randomized, vehicle-controlled clinical trial. Arch Dermatol 2004; 140: 813-816.
26. Loven K, Stein L, Furst K, Levy S. Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis. Clin Ther 2002; 24: 990-1000.
27. Weiss J, Menter A, Hevia O, et al. Effective treatment of actinic keratosis with 0.5% fluorouracil cream for 1, 2, or 4 weeks. Cutis 2002; 70(Suppl 2): 22-29.
28. Labandeira J, Pereiro M Jr, Valdes F, Toribio J. Intermittent topical 5-fluorouracil is effective without significant irritation in the treatment of actinic keratoses but prolongs treatment duration. Dermatol Surg 2004; 30: 517-520.
29. Jorizzo J, Weiss J, Vamvakias G. One-week treatment with 0.5% fluorouracil cream prior to cryosurgery in patients with actinic keratoses: a double-blind, vehicle-controlled, long-term study. J Drugs Dermatol 2006; 5: 133-139.
30. Smith SR, Morhenn VB, Piacquadio DJ. Bilateral comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% 5-fluorouracil cream in the treatment of actinic keratoses of the face and scalp. J Drugs Dermatol 2006; 5: 156-159.
31. Yentzer B, Hick J, Williams L, et al. Adherence to a topical regimen of 5-fluorouracil, 0.5%, cream for the treatment of actinic keratoses. Arch Dermatol 2009; 145: 203-205.
32. Fariba I, Ali A, Hossein SA, et al. Efficacy of 3% diclofenac gel for the treatment of actinic keratoses: a randomized, double-blind, placebo controlled study. Indian J Dermatol Venereol Leprol 2006; 72: 346-349.
33. Wolf JE Jr, Taylor JR, Tschen E, Kang S. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol 2001; 40: 709-713.
34. Rivers JK, Arlette J, Shear N, et al. Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dermatol 2002; 146: 94-100.
35. Nelson C, Rigel D, Smith S, et al. Phase IV, open-label assessment of the treatment of actinic keratosis with 3.0% diclofenac sodium topical gel (Solaraze). J Drugs Dermatol 2004; 3: 401-407.
36. Berlin JM, Rigel DS. Diclofenac sodium 3% gel in the treatment of actinic keratoses postcryosurgery. J Drugs Dermatol 2008; 7: 669-673.
37. Camm AJ, Reiffel JA. Defining endpoints in clinical trials on atrial fibrillation. Eur Heart J Suppl 2008; 10(Suppl H): H55-H78.
38. Gupta AK, Davey V, Mcphail H. Evaluation of the effectiveness of imiquimod and 5-fluorouracil for the treatment of actinic keratosis: critical review and meta-analysis of efficacy studies. J Cutan Med Surg 2005; 9: 209-214.
39. Kaur RR, Alikahn A, Mailbach HI. Comparison of topical 5-fluorouracil formulations in actinic keratosis treatment. J Dermatolog Treat 2010; 21: 267-271.
40. Rivers JK, Wolf J. Assessing clinically meaningful end points for the management of actinic keratosis with diclofenac 3% gel. Acta Derm Venereol 2007; 87: 188-189.
41. Pirard D, Vereecken P, Mélot C, Heenen M. Three percent diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses: a meta-analysis of the recent studies. Arch Dermatol Res 2005; 297: 185-189.
42. Cockerell CJ. Histopathology of incipient intraepidermal squamous cell carcinoma "actinic keratosis". J Am Acad Dermatol 2000; 2(1 pt 2): S11-S17.
43. Chamberlain AJ, Kurwa HA. Photodynamic therapy: is it a valuable treatment option for actinic keratoses? Am J Clin Dermatol 2003; 4: 149-155.
44. Fernández-Guarino M, Harto A, Sánchez-Ronco M, et al. Retrospective, descriptive, observational study of multiple actinic keratoses with topical methyl aminolevulinate and red light: results in clinical practice and correlation with fluorescence imaging. Actas Dermosfiliogr 2008; 99: 779-787.
45. Swanson N, Abramovits W, Berman B, et al. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles. J Am Acad Dermatol 2010; 62: 582-590.
46. Ostertag JU, Quaedvlieg PJ, van der Geer S, et al. A clinical comparison and long-term follow-up of topical 5-fluorouracil versus laser resurfacing in the treatment of widespread actinic keratoses. Lasers Surg Med 2006; 38: 731-739.
47. Price NM. The treatment of actinic keratoses with a combination of 5-fluorouracil and imiquimod creams. J Drugs Dermatol 2007; 6: 778-781.
48. Resnick L, Rabinovitz H, Binninger D, et al. Topical sulindac combined with hydrogen peroxide in the treatment of actinic keratoses. J Drugs Dermatol 2009; 8: 29-32.
49. Schlaak M, Simon JC. Topical treatment of actinic keratoses with low-dose 5-fluorouracil in combination with salicylic acid - pilot study. J Dtsch Dermatol Ges 2010; 8: 174-178.
50. Mastrolonardo M. Topical diclofenac 3% gel plus cryotherapy for treatment of multiple and recurrent actinic keratoses. Clin Exp Dermatol 2009; 34: 33-35.
51. Shaffelburg M. Treatment of actinic keratoses with sequential use of photodynamic therapy and imiquimod 5% cream. J Drugs Dermatol 2009; 8: 35-39.
52. Gilbert DJ. Treatment of actinic keratoses with sequential combination of 5-fluorouracil and photodynamic therapy. J Drugs Dermatol 2005; 4: 161-163.
53. Van Der Geer S, Krekels GA. Treatment of actinic keratoses on the dorsum of the hands: ALA-PDT versus diclofenac 3% gel followed by ALA-PDT. A placebo-controlled, double-blind, pilot study. J Dermatolog Treat 2009; 1: 1-7.
54. Hodari KT, Nanton JR, Carroll CL, et al. Adherence in dermatology: a review of the last 20 years. J Dermatolog Treat 2006; 17: 136-142.
55. Alt SM, Brodell RT, Balkrishnan R, Feldman SR. Poor adherence to treatments: a fundamental principle of dermatology. Arch Dermatol 2007; 143: 912-915.
56. Hess LM, Saboda K, Malone DC, et al. Adherence assessment using medication weight in a phase IIb clinical trial of difluoromethylornithine for the chemoprevention of skin cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 2579-2583.
57. Lebwohl M, Melgaard A, Xu Z. Randomized, parallel-group, double-blind, vehicle-controlled, multicenter phase 3 study of the efficacy and safety of PEP005 (ingenol mebutate) gel, 0.015% in patients with actinic keratoses on the head. Presented at: 22nd World Congress of Dermatology; 24-29 May 2011; Seoul, Korea. Poster P2181.
58. Feldman SR. Improving adherence to topical treatment. Cutis 2009; 83: 215-217.